1. Scrip
  2. >>Focus On Asia

Takeda Continues To Shed Pipeline Assets In Roivant Deal

 
• By Ian Haydock

Takeda has set up a new company with Roivant to expedite the development of relugolix, an oral GnRH antagonist, for indications including prostate cancer and endometriosis.

In a move that marks a continued shedding of selected non-core assets, Takeda Pharmaceutical Co. Ltd. has set up with partner Roivant Sciences Ltd. a new company to develop a late clinical stage molecule that has shown potential in both oncology and women's health indications.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.